a, a N Clinical Trials
A listing of a, a N clinical trials actively recruiting patients volunteers.
Found 1863 clinical trials
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate …
- 0 views
- 19 Feb, 2024
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
It is a multicenter, open-Label, randomised phase 2 study to compare the efficacy and safety study of R2-MTX chemotherapyLenalidomide, Rituximab and Methotrexatewith R-MTX chemotherapyRituximab and Methotrexate as first-line regimens in the treatment of newly diagnosed primary central nervous system lymphoma.2-year Progression free survival (PFS) is the primary endpoint.
- 0 views
- 19 Feb, 2024
Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder
Considering the fact that aged population is rapidly growing, it has become a critical issue to find more effective medications for these two disorders. The aim of this project is to examine the effectiveness and safety of DAAOI-P treatment for PD with dementia.
- 0 views
- 19 Feb, 2024
Primary Percutaneous Pericardiotomy for Malignant Pericardial Effusion (PMAP)
Pericardial effusion is a common complication in patients with metastatic malignancy. While pericardiocentesis provide effective relieve from life-threatening situation such as cardiac tamponade, recurrence of pericardial effusion after pericardiocentesis is common.
- 0 views
- 19 Feb, 2024
Consolidative Radiotherapy Versus Observation for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy
This is a phase II, multicenter, randomized open-label and comparative study designed to evaluate whether local consolidative radiotherapy improves overall survival as compared with standard management in patients with limited metastatic urothelial bladder cancer and without progression following first-line systemic therapy.
- 2 views
- 19 Feb, 2024
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours.
- 0 views
- 19 Feb, 2024
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
Half of the patients will receive tocotrienol and the other half placebo. Treatment is planned for a period of maximum six months and will be discontinued earlier in case of progression or unacceptable toxicity.
- 0 views
- 19 Feb, 2024
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors harboring PIK3CA mutations, candidates to receive maintenance HP after first line …
- 0 views
- 19 Feb, 2024
Personalized Performance Optimization Platform (P-POP)
To help mitigate these risks, Massachusetts General Hospital, along with collaborators at the Massachusetts Institute of Technology, will investigate a novel, personalized and scalable, closed-loop platform technology for on-board behavioral health management-one which adapts the local working environment to optimize performance based on biosensor feedback.
- 0 views
- 21 May, 2025
Prophylactic Infusion of Calcium Gluconate Reducing the Rate of Hypocalcaemia After Total Thyroidectomy
Post-total thyroidectomy hypocalcaemia is a common complication with the rate ranging from 13-49% in a meta-analysis. However, the rate in UMMC in 2018 and 2019 were 40% and 23% respectively.
- 0 views
- 19 Feb, 2024